Archived Policies - Medicine

Bioimpedance Devices for Detection of Lymphedema


Effective Date:04-15-2014

End Date:03-14-2015


Devices using bioimpedance (bioelectrical impedance spectroscopy) are considered experimental, investigational and/or unproven for use in the diagnosis, surveillance, or treatment of patients with lymphedema, including use in subclinical secondary lymphedema.


Secondary lymphedema may develop following surgery for breast cancer. Bioelectrical impedance is being studied as a diagnostic test for lymphedema, particularly for subclinical disease.


Secondary lymphedema of the upper extremity may develop following surgical treatment for breast cancer; it has been reported in approximately 25% to 50% of women following mastectomy. This can be a chronic, disfiguring condition. It results from lymphatic dysfunction or disruption and can be difficult to accurately diagnose and manage. One challenge is identifying the presence of clinically significant limb swelling through simple noninvasive methods. Many techniques have been used for documenting lymphedema including measuring differences in limb volume (volume displacement) and limb circumference. A number of newer techniques are being evaluated, including bioimpedance with use of bioimpedance spectroscopy (BIS) analysis, which uses resistance to electrical current in comparing the composition of fluid compartments. BIS is based on the theory that the amount of opposition to flow of electric current (impedance) through the body is inversely proportional to the volume of fluid in the tissue. In lymphedema, with the accumulation of excess interstitial fluid, tissue impedance decreases.

The detection of subclinical lymphedema, that is, the early detection of lymphedema before clinical symptoms become apparent, is another area of study. Detection of subclinical lymphedema (referred to as Stage 0 lymphedema) is problematic. Subclinical disease may exist for months or years before overt edema is noted. This approach generally involves comparison of preoperative (ie, baseline) with postoperative measurements, since existing differences between upper extremities (like the effects of a dominant extremity) may obscure early, subtle differences resulting from the initial accumulation of fluid. Bioimpedance has been proposed as 1 diagnostic test for this condition. Those who support this approach to diagnose subclinical disease believe that early treatment of subclinical lymphedema should result in less severe chronic disease.

Regulatory Status

One of the devices is the ImpediMed L-Dex™ U400 cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process in 2007. According to FDA documents, the device is indicated as an aid in the clinical assessment of unilateral lymphedema of the arm in women. It is not intended to diagnose or predict lymphedema.


Assessment of a diagnostic technology typically focuses on 3 parameters: (1) technical performance; (2) diagnostic performance (sensitivity, specificity, and positive and negative predictive value) in appropriate populations of patients; and (3) demonstration that the diagnostic information can be used to improve patient outcomes (clinical utility). While in some cases, tests can be adequately evaluated using technical and diagnostic performance, when a test identifies a new or different group of patients with a disease, randomized controlled trials (RCTs) are needed to demonstrate impact of the test on the net health outcome.

Literature Review

Technical performance

Technical performance of a device is typically assessed with 2 types of studies, those that compare test measurements with a gold standard and those that compare results taken with the same device on different occasions (test-retest). While there is no absolute gold standard for diagnosis of lymphedema, the de facto gold standards are limb volume and/or limb circumference. Studies that address technical performance of bioimpedance devices are described below.

A 2010 publication by Czerniec et al. reported on measurement of lymphedema in a small group of patients, 33 with lymphedema and 18 without.(1) This study was to determine the relationship between physical methods of measuring lymphedema and self-reported swelling. Measurement techniques included self-report, bioimpedance spectroscopy, perometer, and the truncated cone method. The authors noted that the physical measurement tools were highly reliable with high concordance (0.89 to 0.99, respectively). In this study, self-report correlated moderately with physical measurements (0.65 to 0.71, respectively) and was moderately reliable. The authors concluded that lymphedema assessment methods are concordant and reliable but not interchangeable.

In a U.S.-based study published in 2007, Warren and colleagues evaluated 15 patients with upper- or lower-extremity secondary lymphedema documented by lymphoscintigraphy, along with 7 healthy controls using bioimpedance spectroscopy (BIS) analysis.(2) In addition, both the affected and unaffected limbs in lymphedema patients were evaluated so patients also served as their own controls. According to BIS in the lymphedema patients, the average ratio of current flow of the affected limb to the unaffected limb (the impedance ratio) was 0.9 (range, 0.67 to 1.01). In the control group, the average impedance ratio was 0.99 (range, 0.95 to 1.02). Lower impedance ratio values correlated with higher levels of accumulated fluid.

Diagnostic performance

A technology assessment on the diagnosis and treatment of secondary lymphedema, performed under contract from Agency for Healthcare Research and Quality (AHRQ) by the McMaster University Evidence-based Practice Center, was released in May 2010.(3) The assessment identified 8 studies that reported the sensitivity and specificity of tests to diagnose secondary lymphedema. Two of these studies evaluated bioimpedance devices, Cornish et al. 2001(4) and Hayes et al. 2008,(5) and are briefly described below.

Cornish et al. in Australia followed 102 patients after treatment for breast cancer.(4) Twenty patients developed lymphedema in the 24-months follow-up period, and in these 20 cases, multifrequency bioelectrical impedance analysis (MFBIA) predicted the onset of the condition up to 10 months before the condition was diagnosed clinically. Estimates of the sensitivity and specificity were both approximately 100%. At the time of detection by MFBIA, only one of the patients had a positive test result from the total limb volume determined from the circumferential measures.

In another study from Australia, Hayes et al. noted that the point prevalence of lymphedema varies according to the approach to diagnosis.(5) In this study, lymphedema status was assessed at 3-month intervals between 6 and 18 months postsurgery in a sample of Australian women with unilateral, invasive breast cancer, using 3 methods: bioimpedance spectroscopy, difference between sum of arm circumferences (SOAC), and self-report. Depending on the method, point prevalence ranged between 8% and 28%, with 1 in 5 to 2 in 5 women experiencing lymphedema at some point in time. According to the technology assessment, the sensitivity and specificity of bioimpedance compared to SOAC was 42% and 88%, respectively and the sensitivity and specificity of bioimpedance compared to self-report was 61% and 59%, respectively.

More recently, in 2011, Smoot et al. reported on diagnostic test characteristics including sensitivity, specificity, and area under the receiver-operating-characteristic (ROC) curve for a number of tests used in the diagnosis of breast cancer-related lymphedema. (6) For this study, a total of 141 women were classified as having (n=70) or not having (n=71) breast cancer-related lymphedema (BCRL) based on past diagnosis by a healthcare provider. Areas under the curve for a number of bioimpedance measures and volume measures were in the 0.79 to 0.88 range, with overlap in confidence intervals. Given questions about the standard used for diagnosis and apparent lack of patients with subclinical lymphedema, this study provides little new information. Finally, in a study from Australia, Ward and colleagues concluded that the impedance ratio thresholds for early detection of lymphedema remain suitable for clinical use with present-day analyzers.(7)

In 2012, Vicini et al. published a retrospective analysis of data from 64 women who underwent surgery for breast cancer and had pre- and postsurgical measurements of bioelectrical impedance assessment using an ImpediMed L-Dex device.(8) Postsurgical measurement occurred within 90 days of surgery and before radiation therapy or chemotherapy. Change in the lymphedema index ratios (LIR) pre- and postprocedure was compared. LIR was defined as the difference in volume or impedance between the affected and nonaffected arm. The authors did not discuss a reference standard test. For the group as a whole, median LIR was 0.5 at baseline and the median change in LIR after surgery was 1.1. The authors noted that, although differences between groups were not statistically significant, there appeared to be a greater change in LIR pre- and postsurgery in patients who received more aggressive treatment e.g., larger numbers of nodes removed or dissection of axillary nodes compared to sentinel node only. The study did not include a reference standard test and did not report sensitivity and specificity of bioelectrical impedance analysis.

Clinical utility

The ideal study design is a randomized controlled trial (RCT) comparing health outcomes in patients who were managed with and without the use of bioimpedance devices; no studies of this type were identified.

A related question is whether early detection and treatment of subclinical lymphedema, using a bioimpedance device or another detection method, improves health outcomes. The literature on treatment shows variability among studies regarding response to therapy for secondary lymphedema. Some studies found that mild disease was more responsive to treatment; other studies did not. Similarly, when duration of symptoms was reported, there was no clear relationship between duration of the edema and response to treatment.

A study by Stout Gergich et al., published in 2008, is frequently cited as support for the early detection and treatment of subclinical lymphedema.(9) In this study, lymphedema was identified in 43 of 196 women who participated in a prospective breast cancer morbidity trial. Limb volume was measured preoperatively and at 3-month intervals after surgery using perimetry (another evolving technique). If an increase of greater than 3% in upper limb volume developed compared with the preoperative volume, a diagnosis of lymphedema was made and a compression garment intervention was prescribed for 4 weeks. Statistical analysis was a repeated-measures analysis of variance by time and limb (p≤0.001) comparing the lymphedema cohort with an age-matched control group. In this study, the time to onset of lymphedema averaged 6.9 months postoperatively. The mean (± standard deviation) affected limb volume increase was 83 mL (±119) at lymphedema onset compared with baseline. Of note, clinical lymphedema is generally felt to be apparent when 200 mL of fluid accumulates. After the intervention, a statistically significant mean 48 mL (±103) volume decrease was realized. The mean duration of the intervention was 4.4 weeks. Volume reduction was maintained at an average follow-up of 4.8 months after the intervention. The authors concluded that a short trial of compression garments effectively treated subclinical lymphedema. This study does not answer the key question; that is, whether net health outcome was improved by early intervention. In addition, the role of novel diagnostic testing compared to the use of the de facto gold standard tests (limb volume or circumference) also needs to be evaluated.

Another study on whether early detection and treatment of subclinical lymphedema improves health outcomes was published in 2009 by Boccardo et al.(10) The study did not involve the use of bioimpedance devices so it cannot be considered evidence that their use improves outcomes. Fifty-five women were randomly assigned to a preventive intervention or control group. The preventive intervention consisted of volumetric (arm volume) measurements and early management of lymphedema once identified. Among the 49 of 55 women (89%) assessed at 2 years, the incidence of secondary lymphedema was 8% in the preventive group and 33% in controls. This is a relatively small study, and the various interventions used may have each played a role in the outcome for this study. Moreover, as noted earlier, the study did not include use of bioimpedance devices.


Bioimpedance, which uses resistance to electrical current in comparing the composition of fluid compartments, could potentially be used as a tool to diagnose lymphedema. There is minimal information about the technical and diagnostic performance of bioimpedance testing in the diagnosis (surveillance) of secondary lymphedema; especially for subclinical disease. In addition, there are no data from comparative clinical trials that demonstrate the impact of this test (bioimpedance) on clinical outcomes (clinical utility). Thus, based on the current scientific evidence, the impact on net health outcome is not known in the diagnosis or management of patients with known or suspected lymphedema, or to detect subclinical lymphedema.


Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.


Disclaimer for coding information on Medical Policies

Procedure and diagnosis codes on Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

The presence or absence of procedure, service, supply, device or diagnosis codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. Only the written coverage position in a medical policy should be used for such determinations.

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member’s benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.


The following codes may be applicable to this Medical policy and may not be all inclusive.

CPT Codes

93702, 0239T



ICD-9 Diagnosis Codes

Experimental, investigational and/or unproven for all diagnoses

ICD-9 Procedure Codes


ICD-10 Diagnosis Codes

Experimental, investigational and/or unproven for all diagnoses

ICD-10 Procedure Codes


Medicare Coverage:

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <


  1. Czerniec SA, Ward LC, Refshauge KM et al. Assessment of breast cancer-related arm lymphedema-comparison of physical measurement methods and self-report. Cancer Invest 2010; 28(1):54-62.
  2. Warren AG, Janz BA, Slavin SA et al. The use of bioimpedance analysis to evaluate lymphedema. Ann Plast Surg 2007; 58(5):541-3.
  3. Oremus M, Walker K, Dayes I et al. Technology Assessment: Diagnosis and treatment of secondary lymphedema. 2010. Available online at: Last accessed October, 2013.
  4. Cornish BH, Chapman M, Hirst C et al. Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology 2001; 34(1):2-11.
  5. Hayes S, Janda M, Cornish B et al. Lymphedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence, and identifiable risk factors. Lymphology 2008; 41(1):18-28.
  6. Smoot BJ, Wong JF, Dodd MJ. Comparison of diagnostic accuracy of clinical measures of breast cancer-related lymphedema: area under the curve. Arch Phys Med Rehabil 2011; 92(4):603-10.
  7. Ward LC, Dylke E, Czerniec S et al. Confirmation of the reference impedance ratios used for assessment of breast cancer-related lymphedema by bioelectrical impedance spectroscopy. Lymphat Res Biol 2011; 9(1):47-51.
  8. Vicini F, Shah C, Lyden M et al. Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic. Clin Breast Cancer 2012; 12(2):133-7.
  9. Stout Gergich NL, Pfalzer LA, McGarvey C et al. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 2008; 112(12):2809-19.
  10. Boccardo FM, Ansaldi F, Bellini C et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology 2009; 42(1):1-9.
  11. Bioimpedance devices for Detection of Lymphedema. Chicago, Illinois: Blue Cross Blue Shield Association Medical Policy Reference Manual (November 2013) Medicine 2.01.82.

Policy History:

Date                Reason

4/15/2014        Document updated with literature review. Coverage unchanged.

7/15/2010        New medical document. Devices using bioimpedance (bioelectrical impedance spectroscopy) are considered experimental, investigational and unproven for use in the diagnosis, surveillance, or treatment of patients with lymphedema, including use in subclinical secondary lymphedema. (Coverage is unchanged. This topic was previously addressed on MED202.018, Plethysmography.)

Archived Document(s):

Back to Top